Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.6 million.

  • Fulcrum Therapeutics' Consolidated Net Income rose 968.38% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.5 million, marking a year-over-year decrease of 19843.69%. This contributed to the annual value of -$9.7 million for FY2024, which is 9000.87% up from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Consolidated Net Income stood at -$19.6 million, which was up 968.38% from -$17.3 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Consolidated Net Income high stood at $55.4 million for Q2 2024, and its period low was -$34.1 million during Q2 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was -$23.6 million (2021), whereas its average is -$18.6 million.
  • In the last 5 years, Fulcrum Therapeutics' Consolidated Net Income skyrocketed by 33297.73% in 2024 and then plummeted by 13121.51% in 2025.
  • Fulcrum Therapeutics' Consolidated Net Income (Quarter) stood at -$23.5 million in 2021, then dropped by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then fell by 18.27% to -$19.6 million in 2025.
  • Its Consolidated Net Income was -$19.6 million in Q3 2025, compared to -$17.3 million in Q2 2025 and -$16.6 million in Q4 2024.